On World Cancer Day, Donald Miller M.D., Ph.D. - Professor at the University of Louisville School of Medicine, Brown Cancer Center, discussed, "45 Years of Evolution in the Treatment of Melanoma; Payoff of Clinical and Basic Research."

Donald M. Miller, M.D., Ph.D., FRSM, Professor of Medicine, Pharmacology and Toxicology, and Biochemistry and Microbiology, James Graham Brown Professor of Oncology, and Director Emeritus, UofL Health - James Graham Brown Cancer Center at the University of Louisville School of Medicine, presented “40 Year Evolution of Melanoma Treatment: Death of the Miracle List" at University of Louisville Department of Medicine Grand Rounds on September 24, 2020.


Dr. Miller’s talk focused on discussing the principals of immunotherapy for melanoma, explaining the history of melanoma treatment and role of basic science in developing new therapies, and identifying principles of adjuvant treatment of solid tumors and role of immunotherapy in adjuvant treatment.


Presented by the UofL Division of Medical Oncology & Hematology.

Understand the key features of ephilides, lentigos, junctional nevi, compound nevi, intradermal nevi, blue nevi, dysplastic nevi, Spitz nevi, and other pigmented entities along with common diagnostic approaches and immunohistochemical studies.

In this lecture aimed at pathology residents I discuss current classification, staging and some clinical-molecular features related to gastric malignancies.
#GIPath #OUPath #Pathresidents #Things2Know
Please share this with others who may be interested, and subscribe to the channel so you will receive notice as new videos are uploaded.
You can reach out to me directly via:
Facebook: Lewis Hassell
Twitter: @HassellLewis
or by email at lewis-hassell@ouhsc.edu
More good content available at my public, pathology-focused Facebook group: Phat Trien GPB VN

Stefani Spranger, PhD, postdoctoral fellow at the University of Chicago, discusses recent findings about why a subgroup of patients with melanoma do not have T cells within their tumor microenvironment.

At the 2016 Society for Melanoma Research (SMR) Congress, Spranger discussed her findings that upregulation of the WNT/beta-catenin pathway within the tumor cell mediates the exclusion of T cells from the microenvironment. This is because a subtype of dendritic cells (CD141-positive) must be present to recruit T cells back into the tumor.

So, even if doctors were to perform adoptive transfer with tumor-specific T cells that are ex-vivo activated, those T cells would not hone back into the tumor environment, according to Spranger.

Presentation given by Janice Mehnert, MD, as part of the AIM at Melanoma’s Patient & Caregiver Symposium on May 16, 2017 at Rutgers Cancer institute of New Jersey.